Ian Pavord and colleagues investigated the role of two widely available biomarkers, fraction of nitric oxide in exhaled air (FeNO) and blood eosinophil count, for predicting response to treatment for exacerbations in mild asthma. This prespecified analysis was done in different treatment groups of the Novel Symbicort Turbuhaler Asthma Reliever Therapy (Novel START) trial, which included 675 patients with mild asthma. The patients were randomly assigned to 52-week treatment with either salbutamol taken as needed, budesonide taken as maintenance therapy plus as-needed salbutamol, or combination budesonide–formoterol taken as needed.

中文翻译：

---

在轻度哮喘中有限使用生物标志物指导治疗。

Ian Pavord及其同事研究了两种广泛使用的生物标记物（呼出气中一氧化氮含量和血液嗜酸性粒细胞计数）在预测对轻度哮喘加重治疗的反应中的作用。这项预先指定的分析是在新型Symbicort Turbuhaler哮喘缓解疗法（Novel START）试验的不同治疗组中进行的，其中包括675例轻度哮喘患者。患者被随机分配接受52周治疗，根据需要服用沙丁胺醇，布地奈德作为维持治疗加必要的沙丁胺醇或布地奈德-福莫特罗联合治疗。